Capital Group Private Client Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Group Private Client Services’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.12M	Sell	18,365 -861	-4%	-$382K	0.13%	70
2026 Q1	$8.59M	Sell	19,226 -4,626	-19%	-$2.16M	0.14%	74
2025 Q4	$10.8M	Sell	23,852 -1,022	-4%	-$441K	0.17%	76
2025 Q3	$9.74M	Sell	24,874 -79,663	-76%	-$33.3M	0.16%	87
2025 Q2	$46.5M	Buy	104,537 +78,905	+308%	+$36.4M	0.4%	62
2025 Q1	$12.4M	Buy	+25,632	New	+$11.9M	0.12%	133
2022 Q2	–	Sell	-57,226	Closed	-$14.9M	–	238
2022 Q1	$14.9M	Buy	57,226 +60	+0.1%	+$14.2K	0.16%	123
2021 Q4	$12.6M	Sell	57,166 -4,971	-8%	-$967K	0.13%	127
2021 Q3	$11.3M	Buy	+62,137	New	+$12.1M	0.13%	126

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Group Private Client Services's VRTX Position: Q2 2026 in Review

Capital Group Private Client Services reduced its Vertex Pharmaceuticals (VRTX) stake by 4.5% in Q2 2026, selling an estimated $382K and leaving 18,365 shares worth $9.12M. The position accounts for 0.13% of the portfolio, ranked #70.

Capital Group Private Client Services first reported a position in VRTX in Q3 2021 and has held it in 9 quarters since. The position peaked at $46.5M in Q2 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Capital Group Private Client Services held 18,365 shares of Vertex Pharmaceuticals worth $9.12M as of Q2 2026.
Capital Group Private Client Services sold 861 Vertex Pharmaceuticals shares in Q2 2026, an estimated $382K.
Vertex Pharmaceuticals made up 0.13% of Capital Group Private Client Services's portfolio in Q2 2026, its #70 holding.
Capital Group Private Client Services first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 9 quarters since.
Capital Group Private Client Services's Vertex Pharmaceuticals position peaked at $46.5M in Q2 2025.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Capital Group Private Client Services's 13F filing for Q2 2026, filed 12 Aug 2026.